Kezar Life Sciences

General Information


We are a clinical-stage biotechnology company, discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. Our lead product candidate, KZR-616, a first-in-class selective immunoproteasome inhibitor, has completed testing in healthy volunteers and is now enrolling a Phase 1b/2 clinical trial in lupus and lupus nephritis. 


Employees: 20
Founded: 2015
Contact Information
Address 4000 Shoreline Court, Suite 300, South San Francisco, CA 94080, US
Phone Number (650) 822-5600
Web Address
View Prospectus: Kezar Life Sciences
Financial Information
Market Cap $269.8mil
Revenues $0 mil (last 12 months)
Net Income $-11.2 mil (last 12 months)
IPO Profile
Symbol KZR
Exchange NASDAQ
Shares (millions): 4.7
Price range $14.00 - $16.00
Est. $ Volume $70.0 mil
Manager / Joint Managers Jefferies/ Cowen/ Wells Fargo Securities/ William Blair
CO-Managers -
Expected To Trade: 6/21/2018
Day: Thursday
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change